TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:28
Fortress Biotech Inc. ( FBIO ) https://www.fortressbiotech.com
2.53USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-69.26%
FBIO
SPY
30.72%
-95.33%
FBIO
SPY
112.82%
-75.73%
FBIO
SPY
201.04%
-92.97%
FBIO
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
18.96
22.22
0.31
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.17
0.23
-1.43
-809.75
0.00
-0.13
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-39.59
81.50
-207.97
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
12.3884
-31.44
-58.93
2.06
Other Earnings and Cash Flow Stats:
Fortress Biotech Inc. ( FBIO ) Net Income TTM ($MM) is -102.22
Fortress Biotech Inc. ( FBIO ) Operating Income TTM ($MM) is -176.34
Fortress Biotech Inc. ( FBIO ) Owners' Earnings Annual ($MM) is -186.40
Fortress Biotech Inc. ( FBIO ) Current Price to Owners' Earnings ratio is -0.31
Fortress Biotech Inc. ( FBIO ) EBITDA TTM ($MM) is -167.33
Fortress Biotech Inc. ( FBIO ) EBITDA Margin is -207.97%
Capital Allocation:
Fortress Biotech Inc. ( FBIO ) has paid 0.00 dividends per share and bought back -1.533239 million shares in the past 12 months
Fortress Biotech Inc. ( FBIO ) has reduced its debt by 61.238 million USD in the last 12 months
Capital Structure:
Fortress Biotech Inc. ( FBIO ) Interest-bearing Debt ($MM) as of last quarter is 75
Fortress Biotech Inc. ( FBIO ) Annual Working Capital Investments ($MM) are -138
Fortress Biotech Inc. ( FBIO ) Book Value ($MM) as of last quarter is -14
Fortress Biotech Inc. ( FBIO ) Debt/Capital as of last quarter is 453%
Other Balance Sheet Stats:
Fortress Biotech Inc. ( FBIO ) has 72 million in cash on hand as of last quarter
Fortress Biotech Inc. ( FBIO ) has 97 million of liabilities due within 12 months, and long term debt 48 as of last quarter
Fortress Biotech Inc. ( FBIO ) has 7 common shares outstanding as of last quarter
Fortress Biotech Inc. ( FBIO ) has 0 million USD of preferred stock value
Academic Scores:
Fortress Biotech Inc. ( FBIO ) Altman Z-Score is -9.63 as of last quarter
Fortress Biotech Inc. ( FBIO ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Fortress Biotech Inc. ( FBIO ) largest shareholder is Goldman Sachs Group Inc owning 162961 shares at 0.41 ($MM) value
Michael S Weiss(an insider) Bought 147058 shares of Fortress Biotech Inc. ( FBIO ) for the amount of $249998.60 on 2023-11-14
31.19% of Fortress Biotech Inc. ( FBIO ) is held by insiders, and 23.19% is held by institutions
Fortress Biotech Inc. ( FBIO ) went public on 2011-11-17
Other Fortress Biotech Inc. ( FBIO ) financial metrics:
FCF:-153.17
Unlevered Free Cash Flow:-67.29
EPS:-2.69
Operating Margin:-39.59
Gross Profit Margin:81.50
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-121.03
Beta:2.06
Buffet's Owners Earnings:-186.40
Price to Owner's Earnings:-0.31
About Fortress Biotech Inc. ( FBIO ) :
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.